118 related articles for article (PubMed ID: 15598955)
1. Phase I/II trial of gene therapy with autologous tumor cells modified with tag7/PGRP-S gene in patients with disseminated solid tumors: miscellaneous tumors.
Moiseyenko VM; Danilov AO; Baldueva IA; Danilova AB; Tyukavina NV; Larin SS; Kiselev SL; Orlova RV; Anisimov VV; Semenova AI; Shchekina LA; Gafton GI; Kochnev VA; Barchuk AS; Kanaev SV; Hanson KP; Georgiev GP
Ann Oncol; 2005 Jan; 16(1):162-8. PubMed ID: 15598955
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: a first clinical phase I/II trial.
Wittig B; Märten A; Dorbic T; Weineck S; Min H; Niemitz S; Trojaneck B; Flieger D; Kruopis S; Albers A; Löffel J; Neubauer A; Albers P; Müller S; Sauerbruch T; Bieber T; Huhn D; Schmidt-Wolf IG
Hum Gene Ther; 2001 Feb; 12(3):267-78. PubMed ID: 11177563
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma.
Märten A; Renoth S; Heinicke T; Albers P; Pauli A; Mey U; Caspari R; Flieger D; Hanfland P; Von Ruecker A; Eis-Hübinger AM; Müller S; Schwaner I; Lohmann U; Heylmann G; Sauerbruch T; Schmidt-Wolf IG
Hum Gene Ther; 2003 Mar; 14(5):483-94. PubMed ID: 12691613
[TBL] [Abstract][Full Text] [Related]
4. [Phase I-II trial of gene therapy with tag-7 modified autologous tumor cells in patients with metastatic solid tumors].
Moiseenko VM; Danilov AO; Baldueva IA; Danilova AB; Tiukavina NV; Larin SS; Kiselev SL; Orlova RV; Semenova AI; Turkevich EA; Shchelkina LA; Anisimov VV; Gafton GI; Kochnev VA; Barchuk AS; Kanaev SV; Khanson KP; Georgiev GP
Vopr Onkol; 2004; 50(3):293-303. PubMed ID: 15318702
[TBL] [Abstract][Full Text] [Related]
5. Adoptive cellular therapy with tumor vaccine draining lymph node lymphocytes after vaccination with HLA-B7/beta2-microglobulin gene-modified autologous tumor cells.
Meijer SL; Dols A; Urba WJ; Hu HM; Smith II JW; Vetto J; Wood W; Doran T; Chu Y; Sayaharuban P; Alvord WG; Fox BA
J Immunother; 2002; 25(4):359-72. PubMed ID: 12142559
[TBL] [Abstract][Full Text] [Related]
6. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.
Nelson WG; Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Kim M; Weber CE; Baccala AA; Goeman MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF
Cancer Chemother Pharmacol; 2000; 46 Suppl():S67-72. PubMed ID: 10950151
[TBL] [Abstract][Full Text] [Related]
7. Interferon-gamma or granulocyte-macrophage colony-stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumor cells from short-term cell line cultures: a randomized phase 2 trial of the cancer biotherapy research group.
Dillman RO; Wiemann M; Nayak SK; DeLeon C; Hood K; DePriest C
J Immunother; 2003; 26(4):367-73. PubMed ID: 12843799
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience.
Galanis E; Hersh EM; Stopeck AT; Gonzalez R; Burch P; Spier C; Akporiaye ET; Rinehart JJ; Edmonson J; Sobol RE; Forscher C; Sondak VK; Lewis BD; Unger EC; O'Driscoll M; Selk L; Rubin J
J Clin Oncol; 1999 Oct; 17(10):3313-23. PubMed ID: 10506635
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: outcome of a phase I study.
Schreiber S; Kämpgen E; Wagner E; Pirkhammer D; Trcka J; Korschan H; Lindemann A; Dorffner R; Kittler H; Kasteliz F; Küpcü Z; Sinski A; Zatloukal K; Buschle M; Schmidt W; Birnstiel M; Kempe RE; Voigt T; Weber HA; Pehamberger H; Mertelsmann R; Bröcker EB; Wolff K; Stingl G
Hum Gene Ther; 1999 Apr; 10(6):983-93. PubMed ID: 10223732
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma.
Fishman M; Hunter TB; Soliman H; Thompson P; Dunn M; Smilee R; Farmelo MJ; Noyes DR; Mahany JJ; Lee JH; Cantor A; Messina J; Seigne J; Pow-Sang J; Janssen W; Antonia SJ
J Immunother; 2008 Jan; 31(1):72-80. PubMed ID: 18157014
[TBL] [Abstract][Full Text] [Related]
11. Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma.
Dudek AZ; Mescher MF; Okazaki I; Math VT; Luo X; Curtsinger JM; Miller JS
Am J Clin Oncol; 2008 Apr; 31(2):173-81. PubMed ID: 18391603
[TBL] [Abstract][Full Text] [Related]
12. Autologous tumor cell vaccination combined with systemic CpG-B and IFN-α promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial.
Koster BD; Santegoets SJAM; Harting J; Baars A; van Ham SM; Scheper RJ; Hooijberg E; de Gruijl TD; van den Eertwegh AJM
Cancer Immunol Immunother; 2019 Jun; 68(6):1025-1035. PubMed ID: 30852622
[TBL] [Abstract][Full Text] [Related]
13. Autologous tumor cell line-derived vaccine for patient-specific treatment of advanced renal cell carcinoma.
Dillman R; Barth N; Vandermolen L; Mahdavi K; Beutel L; de Leon C; DePriest C; Nayak S
Cancer Biother Radiopharm; 2004 Oct; 19(5):570-80. PubMed ID: 15650449
[TBL] [Abstract][Full Text] [Related]
14. Treatment of kidney cancer with autologous tumor cell vaccines of short-term cell lines derived from renal cell carcinoma.
Dillman RO; Barth NM; VanderMolen LA; Garfield DH; De Leon C; O'Connor AA; Mahdavi K; Nayak SK
Cancer Biother Radiopharm; 2001 Feb; 16(1):47-54. PubMed ID: 11279797
[TBL] [Abstract][Full Text] [Related]
15. Phase 1 trial of allogeneic gene-modified tumor cell vaccine RCC-26/CD80/IL-2 in patients with metastatic renal cell carcinoma.
Buchner A; Pohla H; Willimsky G; Frankenberger B; Frank R; Baur-Melnyk A; Siebels M; Stief CG; Hofstetter A; Kopp J; Pezzutto A; Blankenstein T; Oberneder R; Schendel DJ
Hum Gene Ther; 2010 Mar; 21(3):285-97. PubMed ID: 19788391
[TBL] [Abstract][Full Text] [Related]
16. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
Chang AE; Aruga A; Cameron MJ; Sondak VK; Normolle DP; Fox BA; Shu S
J Clin Oncol; 1997 Feb; 15(2):796-807. PubMed ID: 9053507
[TBL] [Abstract][Full Text] [Related]
17. A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma.
Gitlitz BJ; Belldegrun AS; Zisman A; Chao DH; Pantuck AJ; Hinkel A; Mulders P; Moldawer N; Tso CL; Figlin RA
J Immunother; 2003; 26(5):412-9. PubMed ID: 12973030
[TBL] [Abstract][Full Text] [Related]
18. Phase I/IB study of immunization with autologous tumor cells transfected with the GM-CSF gene by particle-mediated transfer in patients with melanoma or sarcoma.
Mahvi DM; Sondel PM; Yang NS; Albertini MR; Schiller JH; Hank J; Heiner J; Gan J; Swain W; Logrono R
Hum Gene Ther; 1997 May; 8(7):875-91. PubMed ID: 9143914
[TBL] [Abstract][Full Text] [Related]
19. Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study.
Möller P; Sun Y; Dorbic T; Alijagic S; Makki A; Jurgovsky K; Schroff M; Henz BM; Wittig B; Schadendorf D
Br J Cancer; 1998 Jun; 77(11):1907-16. PubMed ID: 9667667
[TBL] [Abstract][Full Text] [Related]
20. An Open-Label Study of the Safety and Efficacy of Tag-7 Gene-Modified Tumor Cells-Based Vaccine in Patients with Locally Advanced or Metastatic Malignant Melanoma or Renal Cell Cancer.
Novik AV; Danilova AB; Sluzhev MI; Nehaeva TL; Larin SS; Girdyuk DV; Protsenko SA; Semenova AI; Danilov AO; Moiseyenko VM; Georgiev GP; Baldueva IA
Oncologist; 2020 Sep; 25(9):e1303-e1317. PubMed ID: 32240562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
